Evaluation of real-world outcomes associated with use of a prescription digital therapeutic to treat substance use disorders.

Xiaorui Xiong¹, Stephen Braun¹, Maxine Stitzer², Hilary Luderer¹, Gigi Shafai¹, Brendan Hare¹, Michael Stevenson¹, Yuri Maricich¹

¹Medical Affairs, Pear Therapeutics (US), Boston, Massachusetts, USA.

²Behavioral Pharmacology Research Unit, Friends Research Institute, Baltimore, Maryland, USA.

PubMed PMC DOI PDF

Abstract

BACKGROUND AND OBJECTIVES: Digital therapeutics can expand the reach and fidelity of behavioral treatment for substance use disorders (SUDs). This analysis evaluated real-world engagement and clinical outcomes in patients diagnosed with SUD who were prescribed reSET®, an FDA-authorized prescription digital therapeutic (PDT). METHODS: Patients were prescribed a 12-week PDT comprising 61 therapy le…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.